In addition, doxorubicin has the ability to upregulate cancer cell programmed death-ligand 1 (PD-L1) expression through the initiation of danger signals, stimulating antitumor immunogenicity, through the triggering of cytotoxic T lymphocytes, antigen-presenting cells development, increase in myeloid-derived suppressor cells and or immunosuppressive regulatory T cell reduction [58]. This evidence concerns the gene CD274 and cancer.